London, 2 December 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical group, has received recognition for its progress in supporting the United Nations (UN) Sustainable Development Goals (SDGs).
2 December 2019
Press Release, Sustainability
Hikma has been awarded four out of four stars by Supporting the Goals. This is an improvement from the three stars awarded to the company last year. Stars are awarded when businesses publicly demonstrate plans, commitments, actions and progress towards the SDGs.
“We are proud to receive this increased recognition for our work towards the UN SDGs. We will continue to collaborate with others that share our vision for a better future for generations to come, and better health for our communities,” commented Hana Ramadan, Vice President of Corporate Social Responsibility at Hikma.
Hikma aims to achieve its promise of putting better health within reach by ensuring its products remain accessible to those who need them the most, whilst continuously engaging with its communities to promote healthier lives. Much of Hikma’s work contributes directly towards the achievement of the SDGs. Hikma adopted six goals that align most closely with its business and Corporate Social Responsibility (CSR) strategy. These include: Good Health and Well-being, Quality Education, Gender Equality, Decent Work and Economic Growth, Climate Action as well as Industry, Innovation and Infrastructure.
For more information about Hikma’s support for the UN SDGs, visit: http://www.hikma.com/sustainability/aligning-withthe-un-sdgs/